Trevi Therapeutics, Inc. (TRVI) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-06
(Q2 2026)
— full calendar
Earnings Reports
-
Trevi Therapeutics (TRVI) Q1 2026: $172M Cash Extends Runway to 2030 as Phase 3 Chronic Cough Trials Launch
May 06, 2026
-
Trevi Therapeutics (TRVI) Q4 2025: $188M Cash Runway Extends to 2028, Phase 3 Trials Set for Launch
March 18, 2026
-
Trevi Therapeutics (TRVI) Q3 2025: $115M Raise Extends Runway, Phase 3 Cough Trials Set for 2026
November 14, 2025
-
Trevi Therapeutics (TRVI) Q2 2025: $204M Cash Secured as Phase III Readiness Accelerates
August 08, 2025
-
Trevi Therapeutics (TRVI) Q1 2025: 57% Placebo-Adjusted Cough Reduction Drives Pipeline Inflection
July 05, 2025